Navigation Links
Genasense(R) Chemotherapy Program Yields High Response Rate in Patients with Stage 4 Melanoma
Date:5/30/2008

Related Clinical Study Shows Potential Utility of Short-Course High-Dose

Therapy

BERKELEY HEIGHTS, N.J., May 30 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced preliminary results that have shown a high objective response rate in a pilot study that incorporates the Company's lead oncology product, Genasense(R) (oblimersen sodium) Injection, in a chemotherapy program for patients with advanced melanoma. In this study, Genasense was used to potentially enhance the clinical activity of temozolomide (Temodar(R); Schering Plough, Inc.), the most commonly used anticancer drug for melanoma, combined with Abraxane(R) (paclitaxel protein-bound particles for injectable suspension; Abraxis Bioscience, Inc.). The data will be featured in a presentation at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago on June 1, 2008.

All 14 of the first cohort of patients accrued to this study had non-resectable stage 4 melanoma. None had previously received chemotherapy, and their baseline LDH did not exceed 1.1 times the upper limit of normal. (LDH is a tumor-derived blood marker that was shown to affect the response to Genasense plus chemotherapy in a recent randomized trial.) To date, 6 patients (43%) have achieved major objective responses: one with complete response (CR) after 6 cycles of treatment, and 5 with at least a partial response after only one treatment cycle. Three additional patients have maintained stable disease (SD) after at least three treatment cycles, for an overall clinical benefit response (CR+PR+SD) of 64%.

Laboratory studies showed that Genasense did not alter the expected pharmacokinetics of paclitaxel, and that clinical response was associated with alterations in Bcl-2, a protein that is the molecular target of Genasense. No dose-limiting toxicity was observed. The most commonly observed side-effects were similar to those encountered wi
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
2. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
3. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
4. Genasense(R) Can be Administered by Brief High-Dose IV Infusion
5. Genasense(R) Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress
6. FDA to Extend Review of Data Quality Submission for Genasense(R) in Melanoma
7. FDA Extends Review of Genasense(R) NDA Appeal in Chronic Lymphocytic Leukemia
8. FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data
9. DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma
10. Specialized Genasense(R) Clinical Trials Featured at AACR Meeting
11. Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Oct. 30, 2014 Molecular Profiles Ltd., a ... ) and Maryland -based Xceleron have ... efficiency during clinical development that will be launched at ... week. This partnership extends Molecular Profiles, new ... launched earlier this month. The company also has complementary ...
(Date:10/30/2014)... October 30, 2014 ... beim Aufbau von Kuhmilchverträglichkeit     Kuhmilchproteinallergie ... bei Säuglingen und Kleinkindern. Der bisher übliche ... Ernährung der Babys bzw. deren stillenden Mütter ... dass sich bei einer beträchtlichen Anzahl von ...
(Date:10/30/2014)... 29, 2014 nebulizer is a medical device ... and cystic fibrosis) that converts liquid medication into mist ... the lungs of a patient when inhaled through the ... is dominated by various devices powered by electric current ... asthma, COPD and cystic fibrosis and growing number of ...
Breaking Medicine Technology:Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 3Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3
... Langan, Vice President of Marketing and Business Development, announced ... labeling for sterile intravenous compounded ICU Services at ... May 19-24, 2012 in Orlando, Florida. (Logo: ... care professionals to visit Booth #2668 to see how ...
...  Varian Medical Systems (NYSE: VAR ) will ... and other conditions non-invasively at the 2012 International Conference ... in San Francisco.  "We,re excited about ... not be familiar with radiosurgery as a treatment option ...
Cached Medicine Technology:PharMEDium Highlights Enhanced Labeling for ICU Services at Critical Care Expo 2Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer 2Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer 3Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer 4
(Date:10/30/2014)... October 30, 2014 PreDiabetes Centers ... PreD Store shoppers with a supply of sugardown®, ... to reduce post-meal blood sugar spikes. Learning how to ... an important part of a diabetes prevention plan. , ... receive one complimentary tube of sugardown. The offer expires ...
(Date:10/30/2014)... Reinberg HealthDay Reporter , WEDNESDAY, ... men with prostate cancer who also have certain heart problems ... a new study suggests. , , The therapy in question is ... to reduce levels of male hormones to prevent the growth ... current research, this hormone therapy was linked to triple the ...
(Date:10/30/2014)... Toronto, Canada (PRWEB) October 30, 2014 ... the area’s leading provider of non-medical, in-home senior care, ... activity to increased brain health. , The study, performed ... the ages of 60 and 78 over a week-long ... as opposed to daily physical activity. By examining the ...
(Date:10/30/2014)... 30, 2014 Global prebiotics market is ... to a new study by Grand View Research, Inc. ... for sugar and fat free products owing to increased ... for prebiotics over the forecast period. , View full ... Food & beverage was the largest application segment with ...
(Date:10/30/2014)... South Carolina (PRWEB) October 30, 2014 ... and should be more vigorously exercised to help maintain ... recently authored the book ‘Dementia Express: Lose Your Memory ... book uses counterintuitive reasoning and sometimes conflicting attitudes to ... course for the mind, a reader must decipher the ...
Breaking Medicine News(10 mins):Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 4Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 5Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2
... -- Winner Medical Group Inc.,(OTC Bulletin Board: WMDG) (,Winner Medical, ... quarter ended December 31,2008. The Company,s results are detailed in ... Exchange Commission. , , First Quarter 2009 ... by 33.14% over the first quarter of, ...
... development, today announces that it has appointed Riccardo Nisato, MBA, PhD, ... CH. Dr. Nisato will be responsible for replicating Stemedica,s U.S. ... , ... San Diego, Calif. (PRWEB) February 13, 2009 -- ...
... Feb. 12 The Ensign Group, Inc. (Nasdaq: ... the Ensign(TM) group of skilled nursing, rehabilitative care ... it expects to issue its fourth quarter and ... close on Wednesday, February 18, 2009.(Logo: ...
... and Valentine,s Day LOS ANGELES, Feb. 12 Don,t ... In celebration of National Condom Week, Planned Parenthood Los ... application on Facebook to help remind everyone -- and ... against sexually transmitted diseases (STDs) and unplanned pregnancy. " ...
... , , THURSDAY, Feb. 12 (HealthDay News) -- People exposed ... 44 percent increased risk of developing dementia, a new ... connection between smoking and increased risk for dementia and ... to date showing a link between secondhand smoke and ...
... legislation intended to help reduce cardiovascular disease in ... that could force some women to make tough ... Lisa Murkowski (R-AK) and Congresswomen Lois Capps (D-CA) ... that would expand access to screening and lifestyle ...
Cached Medicine News:Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 2Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 3Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 4Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 5Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 6Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 7Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 8Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 9Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 10Health News:Stemedica Announces the Appointment of Riccardo Nisato, MBA, PhD as Director of Manufacturing and Clinical Business Development for Stemedica International 2Health News:Stemedica Announces the Appointment of Riccardo Nisato, MBA, PhD as Director of Manufacturing and Clinical Business Development for Stemedica International 3Health News:The Ensign Group Schedules 2008 Year End Earnings Call for Thursday, February 19, 2009 2Health News:Planned Parenthood Offers E-Condoms on Facebook 2Health News:Secondhand Smoke Linked to Dementia 2Health News:Stabenow, Murkowski, Capps and Bono Mack Reintroduce HEART for Women Act 2Health News:Stabenow, Murkowski, Capps and Bono Mack Reintroduce HEART for Women Act 3Health News:Stabenow, Murkowski, Capps and Bono Mack Reintroduce HEART for Women Act 4
Inquire...
Inquire...
Inquire...
... Recognized for classic styling, Tura's original ... women with discriminating taste. Tura designs exemplify ... beauty and style with quality and durability. ... details set the Tura woman apart. Rich ...
Medicine Products: